Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Abgenix, AC, accuracy, adequacy, aeroallergen, Allergan, alter, Alzheimer, AMG, antihormonal, APIC, arrive, assigned, Astra, AstraZeneca, automatically, Barr, BCIRG, benchmark, billing, boxed, brining, broader, Cambridge, capecitabine, captured, category, CGI, chosen, cisplatin, daily, Dastgheib, death, delegate, deliverable, derecognition, disability, dispensing, Disproportionate, disproportionately, ditosylate, DLBCL, DMARD, domestic, DSH, edema, EITF, encouraging, ethyl, exact, extrapolate, flattened, flattening, fluoropyrimidine, Forest, forfeited, formula, Gemzar, Genmab, Genzyme, Gilead, Gleevec, Graph, Green, GSK, guide, HERA, Hillsboro, household, Humax, illustrate, imatinib, immunotherapy, imposed, indigent, inflow, Inotek, interferon, interim, intermediary, irrespective, Judge, keyton, Kineret, King, Kourosh, language, Leave, leaving, Letter, Macugen, Magistrate, mantle, MEK, mesylate, methyl, moderate, moderately, monoclonal, monthly, Mylan, Nonqualified, notably, occlusion, Ofatumumab, Omnitrope, Oregon, Orencia, paragraph, PARP, Pennsylvania, Pension, perennial, perpetual, PFS, pharmacy, plateau, point, poly, polymerase, pool, Poor, preceding, precisely, problem, proceed, purported, radiographic, radioimmunotherapy, rare, reactivity, rectal, recurrent, regular, reinvested, remanding, requisite, resubmit, retiree, retrospectively, sabbatical, saleable, Sandoz, satisfaction, Seattle, securitization, shelf, simplified, Singapore, skin, stand, startup, steroid, Stiefel, sum, switched, switching, Task, Telcyta, Telik, theory, tool, triamcinolone, Tykerb, Umbrella, uncertainty, unexercised, unpatentable, unsecured, unvested, upper, VAR, Vectibix, vein, visit, Visudyne, vitro, voluntary, warehousing, warning, waste, Watson, withdrawn, women, Xyotax, Zactima, Zeneca
Removed:
acceptance, administered, Aggregated, alleged, allergy, allocating, assembled, biology, breach, Carlo, cessation, charter, Chiron, consisting, debtor, declared, defending, delivery, directed, discontinued, diversification, dividend, dosage, exchangeable, exclusively, feature, field, finalized, FOLFOX, foreseeable, hedgehog, historic, hypothetical, initiated, interference, interruption, investee, IRS, lock, matched, mentioned, modeled, modeling, modification, Monte, nonrecourse, Northern, occurring, originally, participated, peanut, prescribing, principally, processing, prolonged, Protropin, push, reallege, redeclared, region, repaid, repay, reteplase, scenario, simple, somatrem, subordinated, tangible, temporarily, terminated, territory, trained, training, transferable, unclear, wastage, workforce
Filing tables
Filing exhibits
- 10-K Annual report
- 10.27 First Amendment to Master Lease Agreement and First Amendment to Building Leases Between Genentech and Slough SSF, LLC, Dated October 2, 2006
- 10.32 Second Amendment to the Manufacturing and Supply Agreement Between Genentech and Lonza Biologics PLC, Effective As of 19 May 2006
- 10.33 Third Amendment to the Manufacturing and Supply Agreement Between Genentech and Lonza Biologics PLC, Dated As of November 6, 2006
- 10.38 Agreement and Plan of Merger by and Among Genentech, Inc., Green Acquisition Corporation and Tanox, Inc., Dated As of November 9, 2006
- 10.39 Form of Voting Agreement Between Genentech, Inc. and Certain Stockholders of Tanox, Inc.
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATIONS OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Arthur D. Levinson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Genentech, Inc. on Form 10-K for the year ended December 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Genentech, Inc. on Form 10-K fairly presents in all material respects the financial condition and results of operations of Genentech, Inc.
By: | /s/ ARTHUR D. LEVINSON | ||
Name: Title: Date: | Arthur D. Levinson, Ph.D. Chief Executive Officer February 23, 2007 |
I, David A. Ebersman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Genentech, Inc. on Form 10-K for the year ended December 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Genentech, Inc. on Form 10-K fairly presents in all material respects the financial condition and results of operations of Genentech, Inc.
By: | /s/ DAVID A. EBERSMAN | ||
Name: Title: Date: | David A. Ebersman Executive Vice President and Chief Financial Officer February 23, 2007 |